Search Page

1

Cite

Share

Bispecific anti-OX40/5T4 antibodies for cancer treatment.

Perez-Santos M. Perez-Santos M. Pharm Pat Anal. 2021 Mar;10(2):59-66. doi: 10.4155/ppa-2020-0030. Epub 2021 Mar 12. Pharm Pat Anal. 2021. PMID: 33709801

Cite

Share

2

Cite

Share

OX40 agonists for cancer treatment: a patent review.

Cebada J, Perez-Santos M, Bandala C, Lara-Padilla E, Herrera-Camacho I, Rosas-Murrieta NH, Millán-Pérez Peña L, Monjaraz E, Flores A, Anaya-Ruiz M. Cebada J, et al. Among authors: perez santos m. Expert Opin Ther Pat. 2021 Jan;31(1):81-90. doi: 10.1080/13543776.2021.1825688. Epub 2020 Oct 6. Expert Opin Ther Pat. 2021. PMID: 32945223 Review.

Cite

Share

3

Cite

Share

Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.

Perez-Santos M. Perez-Santos M. Pharm Pat Anal. 2020 Sep;9(5):149-154. doi: 10.4155/ppa-2020-0017. Epub 2020 Sep 22. Pharm Pat Anal. 2020. PMID: 32960139 Review.

Cite

Share

4

Cite

Share

Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment.

Anaya-Ruiz M, Perez-Santos M. Anaya-Ruiz M, et al. Among authors: perez santos m. Pharm Pat Anal. 2021 Dec 8. doi: 10.4155/ppa-2021-0016. Online ahead of print. Pharm Pat Anal. 2021. PMID: 34875853

Cite

Share

5

Cite

Share

Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody.

Perez-Santos M, Anaya-Ruiz M, Sanchez-Esgua G, Villafaña-Diaz L, Barron-Villaverde D. Perez-Santos M, et al. Pharm Pat Anal. 2021 Mar;10(2):67-72. doi: 10.4155/ppa-2020-0035. Epub 2021 Apr 8. Pharm Pat Anal. 2021. PMID: 33829869

Cite

Share

6

Cite

Share

Neurophysiological Mechanisms Related to Pain Management in Bone Tumors.

Romero-Morelos P, Ruvalcaba-Paredes E, Garciadiego-Cázares D, Pérez-Santos M, Reyes-Long S, Alfaro-Rodriguez A, Salcedo M, Mancilla-Ramírez J, Bandala C. Romero-Morelos P, et al. Among authors: perez santos m. Curr Neuropharmacol. 2021;19(3):308-319. doi: 10.2174/1570159X18666201111112748. Curr Neuropharmacol. 2021. PMID: 33176655 Free PMC article.

Cite

Share

7

Cite

Share

LAG-3 antagonists by cancer treatment: a patent review.

Perez-Santos M, Anaya-Ruiz M, Cebada J, Bandala C, Landeta G, Martínez-Morales P, Villa-Ruano N. Perez-Santos M, et al. Expert Opin Ther Pat. 2019 Aug;29(8):643-651. doi: 10.1080/13543776.2019.1642873. Epub 2019 Jul 18. Expert Opin Ther Pat. 2019. PMID: 31291131 Review.

Cite

Share

8

Cite

Share

Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739.

Millán-Pérez Peña L, Martin PS, Herrera-Camacho I, Bandala C, Anaya-Ruiz M. Millán-Pérez Peña L, et al. Among authors: martin ps. Expert Opin Ther Pat. 2020 May;30(5):307-311. doi: 10.1080/13543776.2020.1732352. Epub 2020 Feb 27. Expert Opin Ther Pat. 2020. PMID: 32106724

Cite

Share

9

Cite

Share

Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.

Herrera-Camacho I, Anaya-Ruiz M, Perez-Santos M, Millán-Pérez Peña L, Bandala C, Landeta G. Herrera-Camacho I, et al. Among authors: perez santos m. Expert Opin Ther Pat. 2019 Aug;29(8):587-593. doi: 10.1080/13543776.2019.1637422. Epub 2019 Jul 4. Expert Opin Ther Pat. 2019. PMID: 31241380 Review.

Cite

Share

10

Cite

Share

Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents.

Anaya-Ruiz M, Bandala C, Landeta G, Martínez-Morales P, Zumaquero-Rios JL, Sarracent-Pérez J, Pérez-Santos M. Anaya-Ruiz M, et al. Among authors: perez santos m. Recent Pat Anticancer Drug Discov. 2019;14(1):85-94. doi: 10.2174/1574892813666181031154146. Recent Pat Anticancer Drug Discov. 2019. PMID: 30381087 Review.

Cite

Share